OBJECTIVES:~Determine the safety and tolerability of VEGF Trap in patients with incurable relapsed or refractory solid tumors or non-Hodgkin's lymphoma.~Determine the maximum tolerated dose of this drug in these patients.~Determine the pharmacokinetics of this drug in these patients.~Evaluate the ability of this drug to bind and inactivate circulating vascular endothelial growth factor (VEGF) in these patients.~Determine the dosing regimen that is optimal for neutralization of circulating VEGF in these patients.~Determine whether antibodies to this drug develop in these patients.~Assess, preliminarily, the ability of this drug to alter tumor vascular permeability and tumor growth in these patients.~OUTLINE: This is a dose-escalation study.~Patients receive VEGF Trap subcutaneously once daily on days 1, 29, 36, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 5 additional patients are treated at the MTD.~Patients are followed at 1 and 4 weeks.~PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.~PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.